Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-025 CAR-T in advanced NKG2DL+ solid tumors
NCT06509490Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belumosudil in solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Treatment-Emergent Adverse Events at 3 months, Dose-Limiting Toxicity Rate at 3 months and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
belumosudil
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06509490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509490.